Skip to main content
NASDAQ:CDAK

Codiak BioSciences News Headlines

$17.86
+1.20 (+7.20 %)
(As of 05/14/2021 01:17 PM ET)
Add
Compare
Today's Range
$17.48
$17.87
50-Day Range
$11.72
$20.55
52-Week Range
$7.90
$37.85
Volume604 shs
Average Volume211,641 shs
Market Capitalization$393.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Codiak BioSciences (NASDAQ CDAK) News Headlines Today

SourceHeadline
New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease AreasNew Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas
finance.yahoo.com - May 11 at 8:55 AM
Codiak Appoints Jennifer Wheler, M.D., as Chief Medical OfficerCodiak Appoints Jennifer Wheler, M.D., as Chief Medical Officer
finance.yahoo.com - May 10 at 3:42 PM
Wedbush Comments on Codiak BioSciences, Inc.s Q1 2022 Earnings (NASDAQ:CDAK)Wedbush Comments on Codiak BioSciences, Inc.'s Q1 2022 Earnings (NASDAQ:CDAK)
americanbankingnews.com - May 10 at 4:30 AM
Codiak BioSciences (NASDAQ:CDAK) Posts Quarterly  Earnings Results, Beats Estimates By $0.58 EPSCodiak BioSciences (NASDAQ:CDAK) Posts Quarterly Earnings Results, Beats Estimates By $0.58 EPS
americanbankingnews.com - May 7 at 3:14 PM
Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational ProgressCodiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress
finance.yahoo.com - May 6 at 6:10 PM
Codiak BioSciences, Inc. (NASDAQ:CDAK) Short Interest Up 21.8% in AprilCodiak BioSciences, Inc. (NASDAQ:CDAK) Short Interest Up 21.8% in April
americanbankingnews.com - May 4 at 2:26 PM
Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual MeetingCodiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
finance.yahoo.com - April 27 at 8:01 PM
Data from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications BiologyData from Codiak’s exoSTING™ Preclinical Development Program for the Treatment of Solid Tumors Published in the Nature Research Publication, Communications Biology
finance.yahoo.com - April 22 at 8:16 AM
Have Insiders Been Buying Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares This Year?Have Insiders Been Buying Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares This Year?
nasdaq.com - April 11 at 5:35 PM
Codiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy PathwaysCodiak Presents Data at AACR 2021 Demonstrating Potential of Engineered Exosomes to Enhance the Therapeutic Index of Well-Validated Cancer Immunotherapy Pathways
finance.yahoo.com - April 10 at 9:46 AM
Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational ProgressCodiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
finance.yahoo.com - March 17 at 12:26 PM
Codiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual MeetingCodiak to Present Data from Two Novel Engineered Exosome Therapeutic Candidate Programs at the American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 10 at 8:15 PM
Independent Director Briggs Morrison Just Bought A Handful Of Shares In Codiak BioSciences, Inc. (NASDAQ:CDAK)Independent Director Briggs Morrison Just Bought A Handful Of Shares In Codiak BioSciences, Inc. (NASDAQ:CDAK)
finance.yahoo.com - February 20 at 8:14 AM
Codiak: Pioneering Engineered Exosomal Drug DeliveryCodiak: Pioneering Engineered Exosomal Drug Delivery
seekingalpha.com - February 18 at 6:29 PM
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters OptionCodiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters' Option
benzinga.com - February 17 at 5:04 PM
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ OptionCodiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option
finance.yahoo.com - February 17 at 5:04 PM
Codiak Announces Pricing of $57.8 Million Public Offering of Common StockCodiak Announces Pricing of $57.8 Million Public Offering of Common Stock
finance.yahoo.com - February 12 at 12:53 AM
Codiak Announces Proposed Public Offering of Common StockCodiak Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 9 at 8:28 PM
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) PatientsCodiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients
finance.yahoo.com - February 4 at 8:54 AM
Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular TherapyCodiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
finance.yahoo.com - January 21 at 1:06 PM
What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?
finance.yahoo.com - January 14 at 6:50 PM
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy VolunteersCodiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
finance.yahoo.com - December 30 at 8:40 AM
New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of CancerNew Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of Cancer
finance.yahoo.com - December 21 at 9:30 AM
Codiak BioSciences Inc.Codiak BioSciences Inc.
barrons.com - November 26 at 10:33 PM
Codiak BioSciences, Inc. (CDAK)Codiak BioSciences, Inc. (CDAK)
realmoney.thestreet.com - November 26 at 10:33 PM
Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceCodiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 23 at 10:37 AM
Codiak BioSciences EPS beats by $13.68, beats on revenueCodiak BioSciences EPS beats by $13.68, beats on revenue
seekingalpha.com - November 19 at 8:01 PM
Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational ProgressCodiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress
finance.yahoo.com - November 19 at 8:01 PM
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor ImmunityCodiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity
finance.yahoo.com - November 9 at 8:26 AM
Foghorn Therapeutics, the Latest Biotech to Go Public, Surges in Its Market DebutFoghorn Therapeutics, the Latest Biotech to Go Public, Surges in Its Market Debut
finance.yahoo.com - October 23 at 5:54 PM
Foghorn Therapeutics Is Latest Biotech to Go PublicFoghorn Therapeutics Is Latest Biotech to Go Public
finance.yahoo.com - October 23 at 12:53 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.